Outline of Clinical Research for F-18 PSMA-1007 PET
Scientific title: Diagnostic Performance of PET Imaging for Prostate Specific Membrane Antigen (PSMA)
Ad Statistics
Times Displayed: 49670
Times Visited: 1409 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
Objectives: Objectives of this clinical research are to clarify the diagnostic ability of PSMA-PET and detailed clinical conditions of prostate cancer by performing PET/CT imaging on patients with prostate cancer after injection of F-18-PSMA-1007 solution and comparing the results with those of conventional imaging techniques (CT/bone scintigraphy etc.)
Eligibility: Adult men who are diagnosed with prostate cancer and undergo or will undergo CT scanning and/or bone scintigraphy, and patients who are suspected to have metastasis or recurrence after treatment
Target sample size: 50
Period: September 1, 2019 ~ March 31, 2022
Principal investigator: Tadashi Watabe (Department of Nuclear Medicine, Osaka University Hospital)
Details: See UMIN-CTR Clinical Trial (Unique ID issued by UMIN: UMIN000037697)
The research project is funded by Japan Science and Technology Agency.
About Osaka University
Osaka University was founded in 1931 as one of the seven imperial universities of Japan and now has expanded to one of Japan's leading comprehensive universities. The University has now embarked on open research revolution from a position as Japan's most innovative university and among the most innovative institutions in the world according to Reuters 2015 Top 100 Innovative Universities and the Nature Index Innovation 2017. The university's ability to innovate from the stage of fundamental research through the creation of useful technology with economic impact stems from its broad disciplinary spectrum.
Back to HCB News
